2019 was a year of transformation for the Hochdorf Group, caused in particular by acquisitions in recent years that did not develop as hoped. The extension of the syndicated loan and the sale of the Pharmalys companies were two of the most important measures implemented to stabilise the company. Hochdorf generated a net sales revenue of CHF 456.8 m in 2019 (−18.6 % compared to the previous year). Due to additional capital allowances, value adjustments and provisions, EBIT was CHF −265.3 m, with a loss attributable to shareholders of CHF −239.2 m.